Here are worldwide third-quarter sales figures for some key Pfizer prescription drugs. Except for Enbrel and Prevnar, the decreases are due to generic competition.

PRODUCT NAME MAIN?CONDITION/USE??????3Q?2012?SALES???3Q?2011?SALES??PERCENT?CHANGE

Lipitor High?cholesterol????????$749?million????$2.6?billion???down?71?percent?

Lyrica Fibromyalgia/pain???????$1.04?billion???$961?million???up?8?percent

Enbrel (outside U.S.) Rheumatoid?arthritis????$893?million????$957?million???down?7?percent

Prevnar 13 Pneumococcal?vaccine????$868?million????$1.01?billion??down?14?percent

Celebrex Pain????????????????????$676?million????$643?million???up?5?percent

Viagra Erectile?dysfunction????$517?million????$493?million???up?5?percent

Norvasc High?blood?pressure?????$319?million????$350?million???down?9?percent

Zyvox MRSA?infections?????????$328?million????$321?million???up?2?percent

Sutent Multiple?cancers????????$294?million????$298?million???down?1?percent

Premarin/Prempro Menopause?symptoms??????$262?million????$267?million???down?2?percent

___

Source: Pfizer Inc.